NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN OFFER OF SECURITIES IN ANY JURISDICTION.
THIS ANNOUNCEMENT INCLUDES INSIDE INFORMATION.
IDH receives approval from the FRA for its dual listing on the Egyptian Exchange; trading expected to commence on 20 May 2021
The listing of the EGP-denominated ordinary shares will position IDH as the sole dual-listed Egyptian company on both the Egyptian Exchange and the London Stock Exchange
(Cairo and London)
-
Further to its announcements on 22 March 2021 and 5 May 2021, Integrated Diagnostics Holdings ("IDH," "the Company" or "the Group," IDHC on the London Stock Exchange ("the LSE")), a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, announces that it has received approval from the Egyptian Financial Regulatory Authority ("the FRA") for the dual listing of the Company's ordinary shares on the Egyptian Exchange's ("the EGX") main market under the EGX ticker code IDHC.CA and ISIN code EGS99021C015.